


Product ID P4492 CAS No. 918505-84-7 **Chemical Name**

Synonym

Formula C17H14CIF2N3O3S Formula Wt. 413.83 **Melting Point** Purity ≥98% Solubility DMSO 83 mg/mL (200.56 mM) Water Insoluble Ethanol Insoluble Store Temp -20°C Ship Temp Ambient Description PLX4720 is an orally available ATP-competitive kinase inhibitor specific for mutant (V600E) B-Raf, which is present in a variety of



Product Information



Bulk quanitites available upon request
--

Product ID	Size
P4492	5 mg
P4492	25 mg

cancer subtypes. PLX4720 is an analog of vemurafenib. This compound is being examined as a treatment for unresectable or metastatic melanomas. Inhibition of B-Raf by PLX4720 induces apoptosis and autophagy in tumor cells, resulting in decreased tumor growth and increased survival in vitro and in vivo. Additional downstream effects of B-Raf inhibition by PLX4720 include downregulation of expression of angiogenic factors, enhancement of surface expression of tumor-associated antigens on tumor cells, and alterations of trafficking of local immune cells such as CD8+ T lymphocytes.

References Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15;19(2):393-403. PMID: 23204132.

> Bottos A, Martini M, Di Nicolantonio F, et al. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):E353-9. PMID: 22203991.

Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012 Mar 1;18(5):1386-94. PMID: 22156613.

Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 1;70(13):5213-9. PMID: 20551059.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.